Date: November 18, 2026

KMP / Board / Auditor Changes

Not Specified

Dividend Declaration or Non-Declaration

Not Specified

Board Meeting Outcomes

The Nomination, Remuneration and Compensation Committee of the Company met on Wednesday, November 18, 2026. The committee approved the Grant of 1,907 Restricted Stock Units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.

Financial Results (Standalone & Consolidated)

Not Specified

Auditor’s Report

Not Specified

Disinvestment / Strategic Actions

Not Specified

Other Operational / Legal / Strategic Disclosures

ESOP Grant Details

Brief details of options granted: Grant of 1,907 RSUs to eligible employees as determined by the Nomination, Remuneration and Compensation Committee.

Regulatory compliance: The scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Total number of shares: 1,907 Equity Shares of face value Re. 1 each.

Pricing Formula (Exercise Price): For 1,907 RSUs, the Exercise Price is Re. 1 each i.e. face value per equity share of the Company.

Options Vested (Vesting Schedule): Subject to fulfilment of pre-vesting conditions, RSUs will vest as under: Vesting Criteria of 1,907 RSUs of Re. 1: 3 years from the date of grant based on performance.

Exercise Period: 1,907 RSUs shall be exercisable within a maximum period of 1 (one) year from the date of vesting, subject to the terms of Jubilant Pharmova Employees Stock Option Plan 2018.

Brief details of significant terms: 1 RSU is equal to 1 equity share. RSUs are granted based on tenure and rating of employee.

Additional note: The requirements prescribed under sub-clauses (g) to (k), (m) & (n) of Clause 10 of Para B of Annexure I of SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are not applicable.

Disclosure timing: The disclosure was made on November 18, 2026 at 7:27 PM.

Document availability: The documents were simultaneously posted on the Company's website at www.jubilantpharmova.com.